Manufacturing Considerations for Animal Health Products
Manufacturing veterinary drug products requires a specialized understanding of animal physiology, formulation requirements, and regulatory expectations. While human and veterinary pharmaceuticals share foundational Good Manufacturing Practices (GMP) and Quality by Design (QbD) principles, animal health products present unique challenges related to species diversity, excipient selection, food safety, and environmental impact.
In this issue of The Altascientist, we explore:
- Species-specific formulation strategies: How differences in animal physiology influence dosage forms, drug delivery, and controlled-release technologies.
- Navigating excipient restrictions: Key regulatory, safety, and formulation considerations when selecting excipients for veterinary drug products.
- Manufacturing process validation: A real-world case study demonstrating how process optimization and scientific investigation helped achieve consistent, commercial-scale manufacturing of an extended-release injectable suspension.
Manufacturing Considerations for Veterinary Drug Products
Human and veterinary drug products share many of the same manufacturing foundations, including quality systems, process validation, contamination control, and consistent product quality. However, veterinary manufacturing must account for a broader range of species, dosage forms, and intended uses.
Fierce Biotech: The cost of waiting - What reaching clinical proof-of-concept sooner means for biotech cash burn
The Science of Efficiency: How Integration Can Optimize Early-Phase Drug Development Timelines
The most consequential delays in early drug development often occur between decisions. By aligning nonclinical, clinical, bioanalytical, manufacturing, and CRO services teams around shared milestones, sponsors can reduce avoidable handoffs, support timely decisions, and keep decisions, data, and execution moving together.
What You'll Learn:
- Where gaps between development stages create delays and why generating data on time is only part of the solution.
- How proactive planning and clear accountability help teams translate emerging data into coordinated action.
- including adaptive trial planning, parallel workstreams, and early regulatory alignment.
- The role of project management in multi-site trials, from identifying enrollment risks to coordinating data, teams, and decisions.
- How an integrated development strategy supported a novel incretin-based therapeutic, progressing from safety assessment to proof-of-concept topline results in 22 months.
Closing the Gaps Between Data and Decisions
Increasingly complex therapies require more sophisticated study designs, specialized testing, and coordinated execution. Even when individual teams meet their milestones, a program can lose valuable time if protocol development, assay validation, regulatory planning, and clinical operations are not aligned.
Inside the Minds of Our Nonclinical Experts: Q&A With Julie Forget, Senior Director of Safety Assessment
With 22 years of experience in nonclinical research, Julie Forget, Senior Director of
Safety Assessment, brings extensive expertise in toxicology, study design, and nonclinical development strategy, from early discovery through IND/NDA-enabling studies.
Bioanalysis at the Finish Line: Supporting Clinical Studies
Antifungal Small Molecule Aerosol Application
Inside the Minds of Our Nonclinical Experts: Q&A With Norbert Makori, Vice President of Toxicology
Every Touchpoint Matters: Building a Better Sponsor Experience in Drug Development | By Lisa Pivetta
When you select a drug development partner, scientific expertise, quality, therapeutic experience, timelines, and technology all matter. They are essential to moving your program forward. But there’s another factor that can be just as important to the success of the relationship: what it feels like to work together.